Nexalin Technology, Inc. (NXL) AI Stock Summary

Snapshot

Nexalin is a pre-commercial medical device maker with just $302K in FY 2025 revenue against a $8.2M net loss, over 25 times revenue. Gross margin is a healthy 80%, but sales & marketing alone ran 20x revenue. Cash sits at $1.0M against a $97.2M accumulated deficit, and the company just completed a 1-for-30 reverse split and carries a going-concern warning from auditors.

What's Happening Right Now

• Thu 1st Oct '26 · Distribution deal: On Oct 1, 2026, Nexalin signed a 10-year exclusive distribution and local manufacturing agreement for Brazil and South America, with a binding initial order for 10 devices and a planned 100-device program.
• Mon 28th Sep '26 · Delisting: On Sept 25, 2026, the Nasdaq Hearings Panel granted continued listing but set strict deadlines: $1.00 minimum bid by Sept 28, 2026 and $2.5M stockholders' equity by Jan 4, 2027, with no assurance of compliance.
• Thu 10th Sep '26 · Dilutive raise: On Sept 10, 2026, Nexalin priced a $750K registered direct offering at $0.31/share with attached warrants, plus a $15M equity line, days before its Nasdaq hearing, against a $97.2M accumulated deficit.
• Thu 10th Sep '26 · Debt financing: On Aug 21, 2026, Nexalin issued a $1.17M note to Streeterville Capital with only $1M net proceeds after discounts, carrying punitive default terms and mandatory prepayments from future fundraising.
• Wed 9th Sep '26 · Earnings: Q2 2026 revenue fell 83% YoY to $12,161, the six-month net loss widened to $4.3M, and management disclosed substantial doubt about the company's ability to continue as a going concern.

Bottom Line

Nexalin is a micro-cap in serious financial distress: shrinking quarterly revenue, a going-concern warning, an active Nasdaq delisting fight with hard deadlines into January 2027, and repeated dilutive financings including a fresh reverse split. A new Brazil distribution deal and a strategic commercialization advisor are small positives, but neither changes a balance sheet with $1M in cash against a $97M accumulated deficit. This is a name defined by survival risk, not valuation.